Search results
Gertrude "Trudy" [2] Belle Elion (January 23, 1918 – February 21, 1999) was an American biochemist and pharmacologist, who shared the 1988 Nobel Prize in Physiology or Medicine with George H. Hitchings and Sir James Black for their use of innovative methods of rational drug design for the development of new drugs. [3]
Apr 2, 2014 · Best Known For: American biochemist and pharmacologist Gertrude B. Elion helped develop drugs to treat leukemia and prevent kidney transplant rejection. She won a Nobel Prize for medicine in...
Gertrude B. Elion (born Jan. 23, 1918, New York, N.Y., U.S.—died Feb. 21, 1999, Chapel Hill, N.C.) was an American pharmacologist who, along with George H. Hitchings and Sir James W. Black, received the Nobel Prize for Physiology or Medicine in 1988 for their development of drugs used to treat several major diseases.
- The Editors of Encyclopaedia Britannica
Gertrude Elion (1918–1999) Leukemia, Herpes Drug Pioneer Using a method known as “rational drug design,” Elion and Hitchings were able to successfully interfere with cell growth, giving way to a number of effective drugs for treating leukemia, gout, malaria, herpes, and many other illnesses.
George Hitchings (1905–1998) and Gertrude Elion (1918–1999) diverged from this traditional path by deliberately designing new molecules with specific molecular structures, using what today is termed rational drug design.
May 23, 2024 · Gertrude Belle Elion (1918–1999) By: Eboni E. Andersun. Published: 2024-05-23. Gertrude Belle Elion was a twentieth-century scientist in the US who researched the structure of viral DNA to help develop anti-viral medications. In the 1970s, Elion helped to develop acyclovir, an early anti-viral medication, alongside a team of other researchers.
Jun 3, 2021 · Gertrude Elion. Despite never receiving a PhD, Gertrude Elion was awarded the 1988 Nobel Prize in Medicine. She shared this prize with Sir James Black and her mentor George Hitchings for revolutionizing pharmacology by rejecting the standard trial-and-error approach for rational drug design.
